Palisade Bio, Inc. Common Stock

Day range

$1.27 – $1.35

Open

$1.33

Prev close

$1.33

Volume

798.99K

Market cap

$231.78M

Shares out

174.27M

P/E

—

P/S

463.56

P/B

1.90

P/FCF

—

ROE

-26.2%

ROA

-25.1%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Charter amendmentJun 11, 2026

  On June 11, 2026, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Amendment") with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 300,000,000 shares to 450,000,000 shares. The Amendment became effective upon filing.

• Private placementApr 2, 2026

  On March 27, 2026 (the "Closing Date"), the Company issued and sold 1,536,885 shares (the "Shares") of common stock, par value $0.01 per share ("Common Stock"), of the Company to an affiliate of IH (the "Investor") for a total purchase price of $3.0 million, or $1.952 per Share... The Shares were offered and sold in a transaction exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(a)(2) thereof.

• Warrant or conversionDec 4, 2025

  The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of up to 8,637,810 shares of the Company's common stock underlying certain warrants issued by the Company pursuant to the terms of that certain warrant inducement agreement dated as of July 23, 2025, which is equal to or in excess of 20% of the Company's common stock outstanding prior to the issuance of such warrants.

• Executive compensation changeOct 22, 2025

  On October 22, 2025, the Company approved the termination of the Plan (the "Termination Date"). The Phantom Units granted to J.D. Finley, the Company's Chief Executive Officer, Mitchell Jones, the Company's Chief Medical Officer, and Ryker Willie, the Company's Senior Vice President of Finance under the Plan are unvested as of the Termination Date and such Phantom Units will also terminate as of the Termination Date for no consideration.

• Annual meeting resultsOct 20, 2025

  On October 17, 2025, Palisade Bio, Inc. (the "Company") held its annual meeting of stockholders ("Annual Meeting"). The Company's stockholders elected the three (3) persons listed below as directors, each to serve until the Company's 2026 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.

Days to cover

6.1

Short interest

31.02M

Avg volume

5.12M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
  positiveGlobeNewswire Inc.· Sep 28, 2026
• Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
  positiveGlobeNewswire Inc.· Sep 23, 2026
• Palisade Bio to Participate in Upcoming Investor Conferences
  positiveGlobeNewswire Inc.· Sep 3, 2026
• Palisade Bio Announces Cancellation of Special Meeting of Stockholders
  neutralGlobeNewswire Inc.· Oct 9, 2025
• Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· Jan 3, 2025